¡Ya estamos en ! Descubre más

Ironwood Pharmaceuticals

IRWD

Capitalización de mercado USD 578 M

3.50 USD

-0.27

7.16%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

3.45

-0.05

1.43%

1 día

-7.16%

5 días

-8.38%

1 mes

-16.07%

3 meses

-9.56%

6 meses

-19.17%

En lo que va del año

-18.03%

1 año

125.81%

5 años

-73.9%

10 años

-69.72%

Acerca de: Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Empleados: 100

Atención médica Fabricantes de medicamentos especializados y genéricos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 58.8%

Neutral 35.3%

Negativo 5.9%

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Zacks Investment Research

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?

IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Zacks Investment Research

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Zacks Investment Research

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Ironwood: Medicare Is Not The Problem I Thought It Was

I rate Ironwood Pharmaceuticals, Inc. a buy with a $5.25 fair value. LINZESS generated $143.74 per 30 capsules, close to Medicare's $136 price for 2027. The 44% sales increase was mostly pricing-driven, while demand grew only 4% to 5%.

Ironwood: Medicare Is Not The Problem I Thought It Was

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood.

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Ironwood Pharmaceuticals: High Dependence On Its Next Trial

Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.

Ironwood Pharmaceuticals: High Dependence On Its Next Trial

Zacks Investment Research

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™